Deep Bio Inc.

🌟 Deep Bio Inc.'s Schedule for the Second Half of 2024! 🌟 We are excited to share that Deep Bio Inc. will be showcasing our pioneering AI-driven cancer diagnostics at several major conferences in the latter half of 2024. Here’s where you can find us: 📅 September 7-11, 2024 European Congress of Pathology (ECP) - Florence, Italy 📅 September 15-17, 2024 Digital Diagnostic Summit - Park City, UT, USA 📅 October 10-12, 2024 DINNO 2024 - Seoul, S.Korea 📅 November 3-5, 2024 Pathology Visions 2024 (DPA) - Orlando, FL, USA 📅 December 11-12, 2024 Digital Pathology & AI Congress: Europe - London, UK We invite you to visit our booth, and engage in discussions about the future of cancer diagnostics. Let's connect, collaborate, and pave the way for a brighter future together! #DeepBioInc #AIinHealthcare #CancerDiagnostics #HealthcareInnovation #MedicalConferences

🚀 Deep Bio and ABION Sign MOU to Revolutionize AI-Driven Cancer Diagnostics 🚀 We are thrilled to announce that Deep Bio has signed a Memorandum of Understanding (MOU) with ABION. This strategic partnership is designed to leverage our cutting-edge AI technologies to enhance cancer diagnostics and accelerate the development of life-saving treatments. Through this collaboration, ABION will integrate Deep Bio's advanced AI-driven c-MET IHC interpretation services into their clinical programs, including key pipeline assets like ABN401 (vabametkib) and ABN101. Our DeepCDx solution will play a crucial role in improving patient recruitment and identification, particularly in ABION’s ongoing combination trials involving vabametkib and lazertinib. This partnership highlights our commitment to pushing the boundaries of AI in digital pathology, enabling more precise and efficient clinical trials. Together, we are poised to make significant strides in the fight against cancer, delivering more effective and personalized treatments to patients worldwide. #AI #CancerDiagnostics #ClinicalTrials #Oncology #Innovation #DeepBio #ABION

🔬 Get ready for the 36th European Congress of Pathology! Join our exceptional team as we present our breakthroughs in digital pathology at this prestigious event. 🌟 Explore cutting-edge technologies, connect with leading experts, and discuss exciting collaboration opportunities. Reserve your spot now using QR-code. See you at #ECP2024! #DeepBio #DigitalPathology

🎗️ September is Prostate Cancer Awareness Month! 🎗️ As we mark Prostate Cancer Awareness Month this September, it's a timely reminder of the critical importance of early detection and accurate diagnosis in the fight against prostate cancer. At Deep Bio Inc., we're deeply committed to advancing these efforts through our AI-powered digital pathology solutions. Prostate cancer is one of the most common cancers affecting men, yet with early detection and precise assessment, we can dramatically improve patient outcomes. This is where innovation plays a crucial role. Our team has been at the forefront of developing AI technology that enhances the accuracy and efficiency of prostate cancer detection. By partnering closely with leading healthcare institutions, we aim to empower pathologists around the world to make faster, more accurate diagnoses. This year, we’re proud to have reached significant milestones, including the adoption of our AI models in clinical settings. These advancements are not just about improving technology—they're about ensuring that every patient receives the most accurate diagnosis possible, which can be life-changing. Our tools help detect even the most subtle signs of prostate cancer, allowing for earlier intervention and more personalized treatment plans. However, our journey is ongoing. We're continuously working to refine our technology, collaborate with medical professionals, and stay ahead of the curve in AI and digital pathology. Our goal is to contribute to a future where prostate cancer is detected earlier, assessed more precisely, and treated more effectively. As we observe Prostate Cancer Awareness Month, we encourage everyone in our network to advocate for regular screenings, stay informed about the latest advancements, and support the ongoing fight against this disease. Together, with the power of AI and our collective efforts, we can make a real difference. #ProstateCancerAwareness #AIinHealthcare #DigitalPathology #InnovationInMedicine #DeepBio

We are pleased to announce our participation in the 2024 Digital Diagnostic Summit, taking place from September 15-17 in the beautiful Park City, Utah. As leaders and innovators in digital pathology gather to discuss the latest advancements, Deep Bio Inc. CCO, Grant Carlson will present: “Advancing AI in Prostate Pathology: Developing Reporting Templates for Enhanced Diagnostic Precision.” Stay tuned for more details on our presentation and how we’re contributing to the future of digital diagnostics. If you’re attending the Summit, we’d love to see you there! Feel free to schedule a meeting by leaving a comment below or contacting us via [email protected]. #DigitalPathology #Innovation #Healthcare #2024DigitalDiagnosticSummit #DeepBio

We're thrilled to announce our participation in the 36th European Congress of Pathology! Join us at Booth #9 for an immersive experience featuring live demos and in-depth insights into our cutting-edge AI-based solutions for digital pathology. Discover how we are transforming diagnostics and pioneering advancements in healthcare, positioning ourselves at the forefront of innovation. Don't miss out! Feel free to schedule a meeting or request a personalized demo by leaving a comment below or via Calendly - https://rb.gy/g0xwjp . Let's shape the future of pathology together. See you there! 👋 #cancer #diagnostics

We are honored to share that a member of our Regulatory Affairs team, Hailey L., upon invitation from a Deputy Director at Korea’s Ministry of Food and Drug Safety, recently participated in the Global Harmonization Working Party (GHWP) Joint Meeting from August 6-8, 2024, at the Taiwan Food and Drug Administration. It was a privilege to contribute to the development of international guidelines for “AI-based In Vitro Diagnostic Medical Device (IVD) Software for Digital Pathology” as part of Working Group 2 (WG2). Being at the forefront of these discussions alongside experts from 34 member countries reinforced our commitment to driving innovation and excellence in AI-driven healthcare. This experience not only deepened our understanding of global regulatory practices but also positioned Deep Bio Inc. as a key player in shaping the future of medical technology. We’re excited to apply these insights as we continue to lead in this rapidly evolving field. #AI #DigitalPathology #RegulatoryAffairs #DeepBio #HealthcareInnovation

𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗶𝗻𝗴 𝗗𝗲𝗲𝗽𝗕𝗶𝗼'𝘀 𝗔𝗜-𝗣𝗼𝘄𝗲𝗿𝗲𝗱 𝗣𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗶𝗮𝗴𝗻𝗼𝘀𝘁𝗶𝗰𝘀 : 𝗗𝗲𝗲𝗽𝗗𝘅® 𝗣𝗿𝗼𝘀𝘁𝗮𝘁𝗲 👇 This CE marked AI-based diagnostic tool is a leap forward from the traditional pathology workflow, setting new standards in accuracy and efficiency in a context of pathologists' shortage and diagnostic variability. Here's what professionnals can expect with DeepDx® from Deep Bio Inc.: - 𝗦𝗽𝗲𝗲𝗱 & 𝗔𝗰𝗰𝘂𝗿𝗮𝗰𝘆: AI analysis completes in 30 seconds per core, with 99% sensitivity and 97% specificity. - 𝗔𝘀𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 𝗼𝗳 𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗶𝘀: Lenght and Gleason Scores can be generated automatically. - 𝗘𝘅𝘁𝗲𝗻𝘀𝗶𝘃𝗲 𝗧𝗲𝘀𝘁𝗶𝗻𝗴: Validated on over 700k cores and ensures reproducible and objective results. - 𝗩𝗲𝗿𝘀𝗮𝘁𝗶𝗹𝗲 𝗗𝗲𝗽𝗹𝗼𝘆𝗺𝗲𝗻𝘁 : can be deployed On-Premise and on Cloud. Integrating DeepDx® Prostate into clinical practice ensures enhanced diagnostic accuracy and efficiency, empowering pathologists to deliver precise and reliable diagnoses. #HCK #DeepBio #Prostate #Cancer #AI

Pioneering Digital Pathology in Morocco – DeepDx Prostate Launch at CAP Nations Unies! We are thrilled to announce the successful deployment of DeepDx Prostate at Centre d’Anatomie Pathologique Nations Unies, one of the first labs in Morocco to embrace AI-driven diagnostics. Under the pioneering vision of Dr. Kettani, CAP Nations Unies has now implemented our advanced AI solutions to generate custom, AI-enabled diagnostic reports, setting a new standard in patient care. This deployment marks a significant milestone in our journey towards transforming healthcare through AI, making Dr. Kettani a trailblazer in the real-world clinical application of digital pathology. Thank you to HealthCare Konnect (HCK) - Scaling accuracy in diagnostics and everyone who contributed to this groundbreaking initiative. We are excited to witness the positive impact of our AI technology in enhancing diagnostic accuracy and efficiency. #DeepDxProstate #DigitalPathology #AIinHealthcare #HealthcareInnovation #MedicalTechnology #SuccessStory #ClinicalExcellence